Insulin | Page 15 of 16

Novo Nordisk Presents Positive Phase 2 Data for Ultra-Long-Acting Insulin Degludec

According to a Novo Nordisk press release the company presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association (ADA) in Orlando FL...

Eli Lilly and Walmart to Provide Affordable Insulin

Eli Lilly and Company announced they're teaming up with Walmart to provide an affordable insulin option for people with diabetes. Beginning in mid-September, Lilly's Humulin(R) brand of insulin will be available in Walmart pharmacies...

Lindsey’s Guide to Surviving College with the Big D, The Schedules and Connections Edition

If you can get a schedule that works with your insulin regimen, you’ve been blessed. So try for that...

Oral Insulin AFREZZA Successful at Controlling Blood Sugar Levels in Type 1 Diabetes Patients

MannKind announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard therapy insulin lispro, a rapid acting insulin (also combined with basal insulin), in reducing HbA1c levels in subjects with inadequately controlled type 1 diabetes...

Novo Nordisk to Stop Insulin Sales in Greece

Novo Nordisk has decided to stop sales of its insulin product in Greece following a government decree ordering a 25% price cut in all medicines, according to a BBC report. The company, which claims it is owed 32 million dollars by the Greek state, said that such a price cut would force its business in Greece to run at a loss. The company was also concerned that the compulsory 25% reduction would have a knock-on effect since other countries use Greece as a key reference point for setting drug prices...

Where Have You Flexed?

Novo Nordisk has announced an online insulin pen photo contest. The "Where Have You Flexed?" contest asks people who use the FlexPen to submit photos of themselves with their pen in unique locations. The grand prize winner will receive a trip for two to the Firestone Indy Lights championship in Miami on October 2 to see Charlie Kimball...

Study Shows AFREZZA Safe and Effective in Controlling Blood Glucose Levels

MannKind Corp. announced the results of a two year study comparing the efficacy and safety of AFREZZA (insulin human [rDNA origin]) versus usual diabetes care. The study followed patients for a total of up to two years. The patients were randomly assigned to a treatment regimen of either AFREZZA plus...

Leptin Therapy as a Treatment for Type 1 Diabetes

Leptin, a hormone discovered in 1994 by Rudolph L. Leibel, is produced by fat cells. Leptin plays an important role in regulating appetite and in glucose and fat metabolism. Its discovery pioneered the concept that adipose tissue is not a silent energy-storage organ, but actually an active endocrine organ...

FDA Requests Additional Information From Mannkind Corp. Regarding AFREZZA

MannKind Corporation announced that it has received a Complete Response letter from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for AFREZZA(TM) Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes...

FDA Accepts Biodel’s New Drug Application for Review

Biodel Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug application seeking approval to market VIAject(R) for the treatment of diabetes. VIAject(R) is Biodel's proprietary formulation of recombinant human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin analogs...